See accompanying notes to condensed financial statements.
See accompanying notes to condensed financial
statements.
See accompanying notes to condensed financial statements.
Notes to Condensed Financial Statements
(unaudited)
NOTE 1. THE COMPANY AND BASIS OF PRESENTATION
The Company
Aclarion, Inc., formerly Nocimed, Inc., (the “Company”
or “Aclarion”) is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), and a
proprietary biomarker to optimize clinical treatments. The Company was formed in February 2015, is incorporated in Delaware, and has its
principal place of business in Broomfield, Colorado.
Basis of Presentation
The accompanying condensed financial statements
have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and
pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information.
Accordingly, they do not include all of the information required by U.S. GAAP for complete financial statements. The interim condensed
financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair representation
of the results for the periods presented and should be read in conjunction with the audited financial statements and notes thereto for
the year ended December 31, 2021, which include a complete set of footnote disclosures, including our significant accounting policies.
The audited financial statements and notes thereto for the year ended December 31, 2021, are included in the Prospectus dated April 21,
2022, as filed with the SEC on April 25, 2022, under Rule 424(b)(4). The results for interim periods are not necessarily indicative of
the results that may be expected for a full fiscal year or for any other future period.
Reclassifications
Certain accounts relating to the prior year have
been reclassified to conform to the current period’s presentation. These reclassifications had no effect on the net income or net
assets as previously reported.
Risks and Uncertainties
The Company is subject to various risks and uncertainties
frequently encountered by companies in the early stages of development. Such risks and uncertainties include, but are not limited to,
its limited operating history, competition from other companies, limited access to additional funds, dependence on key personnel, and
management of potential rapid growth. To address these risks, the Company must, among other things, develop its customer base; implement
and successfully execute its business and marketing strategy; develop follow-on products; provide superior customer service;
and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these
or other such risks.
The Company
is also subject to risks and uncertainties as a result of the coronavirus disease (“COVID-19”) pandemic. The pandemic
continues to evolve and its impact on the Company’s business will depend on several factors that are highly uncertain and unpredictable,
including, the efficacy and adoption of vaccines, future resurgences of the virus and its variants, the imposition of governmental lockdowns,
quarantine and physical distancing requirements, patient capacity at hospitals and healthcare systems, the duration and severity of healthcare
worker shortages, and the willingness and ability of patients to seek care and treatment due to safety concerns or financial hardship.
As such, given the dynamic nature of this situation, the Company cannot reasonably estimate the impacts of COVID-19 on our financial condition,
results of operations or cash flows in the future. We are focused on navigating these recent challenges presented by COVID-19 and believe
we are in a strong position to continue to sustain and grow our business.
Initial Public Offering
On April 21, 2022, the registration statement
for our initial public offering (“IPO”) was declared effective. In connection with the effectiveness of the IPO registration
statement:
|
· |
we effected a 1-for-7.47 reverse stock split of our outstanding common stock; |
|
|
|
|
· |
accordingly, all common share amounts and per share data presented in our condensed financial statements have been retrospectively adjusted to reflect the reverse stock split for all periods presented; |
|
|
|
|
· |
we filed a restated Certificate of Incorporation with the State of Delaware and we adopted new restated Bylaws; |
|
|
|
|
· |
certain outstanding common stock warrants were exercised on a net share basis for 60,408 common shares (451,245 pre-split shares); |
|
|
|
|
· |
24,495,004 (pre-split) outstanding shares of our preferred stock were converted into 3,279,117 post-split shares of common stock; |
|
|
|
|
· |
all accrued dividends on our outstanding Series B, B-1, B-2 and B-3 preferred stock were converted to 984,429 post-split common shares; and |
|
|
|
|
· |
all accrued interest on the Company's outstanding secured promissory notes was converted into (i) 426,768 post-split common shares and (ii) 426,768 post-split common stock warrants, with beneficial conversion rates charged to interest expense upon conversion. |
On April 26, 2022, the Company completed its IPO
of 2,165,000 units, at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common
stock warrant with an exercise price of $4.35 per share. Following the commencement of the IPO, the underwriters partially exercised their
over-allotment option and purchased an additional 324,750 common stock warrants. After deducting underwriter's commissions and expenses,
we received net proceeds of approximately $8.6 million and our common stock and warrants started trading on Nasdaq under the ticker
symbols “ACON” and “ACONW”, respectively.
In connection with the IPO, we issued to the representative
of the underwriters a common stock warrant for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants
are exercisable commencing October 26, 2022 and will expire on April 26, 2027.
On April 21, 2022, 1,204,819 outstanding common
stock options previously awarded to the Company's Executive Chairman, Dr. Jeffrey Thramann, vested in connection with the completion of
the IPO pursuant to the terms of such options. The exercise price of these options is $1.94 per share. The options have a 10-year term.
On April 21, 2022, in connection with the IPO,
the Company adopted the 2022 Aclarion Equity Incentive Plan, or “2022 Plan”. Our board of directors has appointed the compensation
committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan. The aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan may not exceed 2,000,000 shares,
subject to adjustments as described in the 2022 Plan.
On April 29, 2022, in connection with the IPO,
a bonus was paid to David Neal and Brent Ness of $100,000 each. On May 13, 2022, in connection with the IPO, a bonus of $130,000 was paid
to James Peacock.
On May 2, 2022, in connection with the IPO, the
Company paid the University of California - San Francisco the amount of $123,828 to satisfy the Indexed Milestone Payment obligation included
within the exclusive license agreement.
Reverse Stock Split
On April 21, 2022, the Company effected a 1-for-7.47
reverse stock split (the “Stock Split”) of its issued and outstanding common stock. As a result of the Stock Split, unless
described otherwise, all references to common stock, options to purchase common stock, share data, per share data and related information
contained in these financial statements have been retrospectively adjusted to reflect the effect of the Stock Split for all periods presented.
In addition, any fractional shares that would otherwise be issued as a result of the Stock Split were rounded up to the nearest whole
share. Further, the number of shares issuable and exercise prices of stock options and warrants have been retrospectively adjusted in
these financial statements for all periods presented to reflect the Stock Split.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
The financial statements include some amounts
that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, and
valuation of capital stock and warrants and options to purchase shares of the Company's preferred and common stock. These estimates may
be adjusted as more current information becomes available, and any adjustment could be significant.
Valuation of Derivative Instruments
Financial Accounting Standards Board (“FASB”)
Accounting Standards Codification (“ASC”) 815-40, Derivatives and Hedging: Contracts on an Entity’s Own Equity,
addresses whether an equity-linked contract qualifies as equity in the entity’s financial statements. Agreements where an entity
has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value
through earnings each reporting period. The Company evaluates its financial instruments, to determine if such instruments are liabilities
or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported
as charges or credits to income.
Fair Value Measurements
The carrying values of the Company’s financial
instruments including cash equivalents, restricted cash, accounts receivable and accounts payable, and notes payable are approximately
equal to their respective fair values due to the relatively short-term nature of these instruments.
Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. Assets and liabilities recorded at fair value in the balance sheets are categorized based upon the level of judgment associated
with the inputs used to measure their fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed
based on market data obtained from independent sources (observable inputs), and (2) an entity’s own assumptions about market participant
assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists
of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1) and the lowest priority to unobservable inputs (Level 3).
Cash and Cash Equivalents
The Company considers all highly liquid
instruments purchased with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents
for all periods presented. The Company maintains cash deposits at several financial institutions, which are insured by the Federal
Deposit Insurance Corporation up to $250,000. The Company’s cash balance may at times exceed these limits. On September
30, 2022, and December 31, 2021, the Company had $2,416,000 and $201,000, respectively, in excess of federally insured limits. The
Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. The
Company maintains no international bank accounts. As of September 30, 2022, $10,000 of the Company’s cash was restricted as
collateral related to the credit card program offered by our bank.
Accounts Receivable, Less Allowance for Doubtful
Accounts
The Company estimates an allowance for doubtful
accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably
possible that the Company’s estimate of the allowance for doubtful accounts will change. The allowance for doubtful accounts was
$0 at September 30, 2022, and December 31, 2021.
Revenue Recognition
Revenues are recognized when a contract with a
customer exists, and at that point in time when we have delivered a Nociscan report to our customer. Revenue is recognized in the amount
that reflects the negotiated consideration expected to be received in exchange for those reports. Following the delivery of the report,
the company has no ongoing obligations or services to provide to the customer. Customers pay no other upfront, licensing, or other fees.
To date, our reports are not reimbursable under any third-party payment arrangements, The Company invoices its customers based on the
billing schedules in its sales arrangements. Payment terms range generally from 30 to 90 days, from the date of invoice.
Liquidity, Capital Resources and Going Concern
The Company believes that the net proceeds from
the April 2022 initial public offering will be sufficient to fund current operating plans into the second quarter of 2023. The Company
has based these estimates, however, on assumptions that may prove to be wrong, and could spend available financial resources much faster
than we currently expect. The Company will need to raise additional funds to continue funding our technology development and commercialization
efforts over the following nine months. Management has plans to secure such additional funding.
As a result of the Company’s recurring losses
from operations, and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding
the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to
the Company’s ability to continue as a going concern.
Share-Based Compensation
The Company issues stock-based compensation awards
to employees and directors in the form of stock options. The Company measures and recognizes compensation expense for all stock-based
awards based on the awards’ fair value. Share-based compensation for stock options awards are measured on the date of grant using
a Black-Scholes-Merton option pricing model.
Awards vest either on a graded schedule or at
the grant date. The Company determines the fair value of each award as a single award and recognizes the expense on a straight-line basis
over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the
fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant.
Deferred Financing Costs
The Company capitalizes certain legal, accounting,
and other fees and costs that are directly attributable to in-process equity financings as deferred offering costs until such financings
are completed. Upon the completion of an equity financing, these costs are recorded as a reduction of additional paid-in capital
of the related offering. Upon the completion of the IPO in April 2022, approximately $1.5 million of offering costs related to the
IPO were reclassified to additional paid-in capital. The Company had no deferred financing costs as of September 30, 2022.
Emerging Growth Company Status
The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies
can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those
standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or
revised accounting standards that have different effective dates for public and private companies.
NOTE 3. RECENT ACCOUNTING PRONOUNCEMENTS
In August 2020, the FASB issued ASU No. 2020-06,
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic
815-40) (“ASU 2020-06”), which simplifies the accounting for convertible instruments. The guidance removes certain accounting
models that separate the embedded conversion features from the host contract for convertible instruments. The guidance also modifies how
certain convertible instruments, that may be settled in cash or shares, impact the calculation of diluted earnings per share. ASU 2020-06
allows for a modified or full retrospective method of transition. This update is effective for emerging growth companies following private
company adoption dates in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early
adoption is permitted. The Company is currently evaluating the potential impact that adoption of this new standard will have on its financial
statements.
In February 2016, the FASB issued its new lease
accounting guidance in ASU 2016-02, Leases (Topic 842). Under the new guidance, lessees will be required to recognize for all leases (with
the exception of short-term leases) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease,
measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control
the use of, a specified asset for the lease term. ASU 2016-02, as subsequently amended for various technical issues, is effective for
emerging growth companies following private company adoption dates in fiscal years beginning after December 15, 2021, and interim periods
within fiscal years beginning after December 15, 2022. The Company has adopted the new guidance, which did not have a material impact
on its financial statements.
NOTE 4. REVENUE
Contract Balances
The timing of revenue recognition, billings, and
cash collections may result in trade, unbilled receivables, and deferred revenues on the balance sheets. At times, revenue recognition
may occur before the billing, resulting in an unbilled receivable, which would represent a contract asset. The contract asset would be
a component of accounts receivable and other assets for the current and non-current portions, respectively. In the event the Company receives
advances or deposits from customers before revenue is recognized, this would result in a contract liability.
NOTE 5. SUPPLEMENTAL FINANCIAL INFORMATION
Balance Sheets
Accrued and other liabilities
Schedule of accrued and other liabilities | |
September 30, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Accrued salaries and expenses | |
| 450,148 | | |
| 340,363 | |
Accrued interest | |
| – | | |
| 356,219 | |
Accrued and other liabilities | |
$ | 450,148 | | |
$ | 696,582 | |
NOTE 6. LEASES
Rent expense for the three months ended September
30, 2022 and 2021 was $1,366 and $16,933, respectively. Rent expense for the nine months ended September 30, 2022 and 2021 was $33,876,
and $48,697, respectively. The Company entered into a subleasing agreement in 2021 and realized $26,340 and $25,140 of sublease income
for the nine months ended September 30, 2022, and 2021. Both the lease and sublease are netted within the general & administrative
line item in the Condensed Statements of Operations. Our current office lease and sublease expired on June 30, 2022.
NOTE 7. INTANGIBLE ASSETS
The Company’s intangible assets are as
follows:
Schedule of intangible assets | |
September 30, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Patents and licenses | |
$ | 2,099,480 | | |
$ | 1,938,858 | |
UC royalty | |
| 200,000 | | |
| 150,000 | |
Other | |
| 5,017 | | |
| 5,017 | |
Total intangible assets gross | |
| 2,304,497 | | |
| 2,093,875 | |
Less: accumulated amortization | |
| (1,087,292 | ) | |
| (949,250 | ) |
Intangible assets, net | |
$ | 1,217,206 | | |
$ | 1,144,625 | |
Patents and licenses costs are accounted for as
intangible assets and amortized over the life of the patent or license agreement and charged to research and development. UC royalties
are paid annually, amortized over twelve months, and charged to cost of revenue.
Amortization expense related to purchased intangible
assets was $33,958 and $33,387 for the three months ended September 30, 2022, and 2021, respectively. Amortization expense related to
purchased intangible assets was $100,541 and $94,762 for the nine months ended September 30, 2022, and 2021, respectively.
NOTE 8. SHORT TERM NOTES AND CONVERTIBLE DEBT
Convertible Notes:
There were no convertible note purchases for the
nine months ending September 30, 2022.
During the year ended December 31, 2021, and 2020,
accredited investors purchased $814,500 and $1,598,488 of our convertible notes, respectively. In addition, the holders of the Company’s
short-term notes exchanged their notes for this issuance of convertible notes. The convertible notes accrued interest at 10.0% per year
and were originally scheduled to mature on December 31, 2020, which the holders agreed to extend until September 30, 2021. While the convertible
notes contained a provision to automatically convert into shares of common stock at a discount to the price in the next Qualified Financing,
the Qualified Financing did not occur prior to the June 30, 2021 maturity date of the convertible notes. In accordance with the terms
of the convertible notes, the principal plus accrued, but unpaid, interest on the convertible notes (aggregating to $3,201,977) was required
to be automatically converted into 4,228,149 Series B-3 Preferred Shares. The Company did not have the Series B-3 preferred shares authorized
for issuance, and the Company established a liability to issue these shares. This liability was adjusted to fair value until the B-3 preferred
shares were authorized and issued December 3, 2021 (See Note 10).
NuVasive, Inc. Convertible Note and SAFE Agreement:
In February 2020, NuVasive and the Company renegotiated
and amended their prior marketing agreement. In consideration of changing the marketing agreement, NuVasive and the Company entered into
a $2.0 million (Simple Agreement for Future Equity “SAFE”) agreement. The SAFE provided that NuVasive would receive $2 million
of capital stock if the Company would raise a minimum of $10.0 million of new capital on or before December 31, 2020, which was later
extended to June 30, 2021. If the $10.0 million was not raised, the Company would issue to NuVasive 1,584,660 Series B-2 preferred shares. The $10.0 million was not raised and the Company issued 1,584,660 Series B-2 preferred shares to NuVasive in December 2021.
The Company recorded the SAFE when issued at its
fair value, which was measured at $2 million, as NuVasive was to receive a variable number of shares with an aggregate value of $2
million.
The Company recorded the liability to issue the
1,584,660 Series B-2 preferred shares at its fair value of $2 million (a per-share value of $1.2621), based on third-party valuations
at June 30, 2021, and marked the liability to fair value on September 30, 2021, and at the time the B-2 preferred shares were issued December
3, 2021.
In March 2020, the Company negotiated an additional
investment agreement with NuVasive whereby NuVasive purchased $308,720 of convertible notes under the same terms as the existing holders
of the Company's convertible notes.
In June 2021, NuVasive’s convertible note
principal plus accrued, but unpaid, interest was converted (in accordance with the terms of all of the convertible notes) into Series
B-3 Preferred shares (see Convertible Notes above). The B-3 preferred shares were issued December 3, 2021.
Cares Act Paycheck Protection Program Loan
(PPP Loan)
The Company did not enter into any Paycheck Protection
Program (“PPP”) loans during the nine months ended September 30, 2022.
In April 2020 and February 2021, the Company entered
into two promissory notes evidencing an unsecured loan (the “Loans”) in the amounts of $245,191 and $125,000, respectively,
made to the Company under the Paycheck Protection Program (the “PPP”). The PPP was established under the CARES Act administered
by the U.S. Small Business Administration.
The PPP promissory notes were to mature in March
2022 (2020 note) and January 2026 (2021 note) and bear interest at a rate of 1% per annum, payable monthly commencing in June 2019 and
November 2020. The Loans could be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from
the Loans could only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on
certain other debt obligations.
The Loans contained customary events of default
relating to, among other things, payment defaults, making materially false and misleading representations to the lender, or breaching
the terms of the Loan documents. The occurrence of an event of default would result in an increase in the interest rate to 18% per annum
and provide the lender with customary remedies, including the right to require immediate payment of all amounts owed under the promissory
note.
Pursuant to the terms of the CARES Act and the
PPP, the Company applied in February 2021 to the lender for forgiveness of the amount due on the Loans. In May 2021, the Company was notified
that 100% of the first loan of $245,191 and related interest of $2,622 had been forgiven, and in August 2021 the Company was notified
that 100% of the second loan of $125,000 and related interest of $698 had been forgiven. The amounts eligible for forgiveness was based
on the amount of Loan proceeds used by the Company for the payment of certain covered costs, including payroll costs (including benefits),
interest on mortgage obligations, rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and
the PPP.
Promissory Notes Payable
In June 2021, the Company issued $2.0 million
of promissory notes that matured at the earlier of the consummation of a Qualified Financing or May 31, 2022. The promissory notes incorporated
the following major attributes: secured by a lien and security interest on substantially all of the Company’s assets; interest
accrues at 33%; holder option to convert the accrued interest into the Company securities being offered in a Qualified Financing
at 30% (i.e. 70% discount) of the price being paid by other investors in the Qualified Financing; and automatic conversion in the
case of a Qualifying IPO of the accrued interest into the Company securities being offered in the Qualifying IPO at 30% (70% discount)
of the price being paid by other investors in the Qualifying IPO. If the promissory notes remained outstanding after May 31, 2022, the
Company had the option to extend the promissory notes upon the payment of an extension fee, which consisted of 150,000 warrants (20,080
warrants post-split) with a five-year term, to purchase shares of the Company’s common stock at a price of $ 0.01 per share ($0.0747
post-split).
On April 21, 2022, the registration statement
for our initial public offering (IPO) was declared effective. In connection with the effectiveness of the IPO registration statement,
all accrued interest on the Company's outstanding secured promissory notes was converted into (i) 426,768 post-split common shares and
(ii) 426,768 post-split common stock warrants, with a $1,299,507 beneficial conversion rate charged to interest expense.
On April 27, 2022, the Company used $2 million
of the IPO proceeds to retire all outstanding secured promissory notes.
NOTE 9. COMMITMENTS AND CONTINGENCIES
Royalty Agreement
The Company has an exclusive license
agreement with the Regents of the University of California to make, use, sell and otherwise distribute products under certain of the
Regents of the University of California’s patents anywhere in the world. The Company is obligated to pay a minimum annual
royalty of $50,000,
and an earned royalty of 4% of net sales. The minimum annual royalty will be applied against the earned royalty due for the calendar
year in which the minimum payment was made. The license agreements expire upon expiration of the patents and may be terminated
earlier if the Company so elects. The U.S. licensed patents that are currently issued expire between 2026 and 2029, without
considering any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity,
or other governmental fees. The Company recorded royalty costs of $12,500
for the three months ended September 30, 2022, and 2021, respectively, and $37,500 for the nine months ended September 30,
2022, and 2021, respectively, which were recorded in cost of revenue.
Additionally, the Company was obligated to make
a cash Indexed Milestone Payment to the Regents of the University of California in the event of either a Change of Control or an Initial
Public Offering (IPO). This cash payment was calculated as follows: 28,532 post-split shares (213,313 pre-split shares) of Company common
stock times the IPO price of $4.34. On May 2, 2022, in connection with the IPO, the Company paid the University of California - San Francisco
the amount of $123,828 to satisfy the Indexed Milestone Payment obligation included within the exclusive license agreement.
Litigation
To date, the Company has not been involved in
legal proceedings arising in the ordinary course of its business. If any legal proceeding occurs, the Company would record a provision
for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated, although
litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control.
Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related
to legal matters that could have a material impact on its results of operations, financial position and cash flows.
Stock Option Grant to our Executive Chairman
In September 2021, the Board of Directions approved
a stock option grant of 1,204,819 post-split shares to Dr. Jeffrey Thramann, our Executive Chairman. These options are conditional, such
that they vest only upon the occurrence of certain specified events, including an IPO, a next round financing, the merger of the Company
with a SPAC, or the sale of the Company. The amount of stock options that will vest upon such specified events depends upon the terms
and timing of the applicable event. In the case of an IPO, the number of shares that will vest is equal to 16.7% of the Company’s
pre-IPO fully diluted shares (inclusive of the portion of Dr. Thramann’s option grant that will become vested). Any remaining portion
of the option grant will be cancelled. The agreement with Dr. Thramann also contains provisions in the event of his voluntary resignation
from the company, as well as other provisions if he is terminated by the Company.
On April 21, 2022, 1,204,819 outstanding common
stock options previously awarded to Dr. Jeffrey Thramann vested in connection with the completion of
the IPO pursuant to the terms of such options. The exercise price of these options is $1.94 per share. The options have a 10-year term.
NOTE 10. STOCKHOLDERS’ EQUITY
The Company filed an Amended and Restated Certificate
of Incorporation on April 21, 2022, as part of the initial public offering (IPO). The Company is authorized to issue two classes of stock
to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company
is authorized to issue is two hundred twenty million (220,000,000) shares. Two hundred million (200,000,000) shares are authorized to
be Common Stock, having a par value per share of $0.00001. Twenty million (20,000,000) shares are authorized to be Preferred Stock, having
a par value per share of $0.00001.
Prior to the IPO, the Company had authorized
two classes of shares. These classes included shares of common stock and preferred stock. There was one authorized series of shares of
common stock and eight existing authorized series of preferred stock: Series A-1, A-2, A-3, A-4, B, B-1, B-2, and B-3.
The preferred shares converted to common shares
on a 1:1 pre-split basis immediately prior to the Stock Split on April 21, 2022. Those common shares were adjusted to reflect the Stock
Split as described in Note 1 Reverse Stock Split.
Preference Amounts | |
Issue Date | |
Total Face Value of Investment | | |
Issue Purchase Price/Share | |
| |
| |
| | |
| |
Series A-1 Preferred Stock | |
12/31/2014 | |
$ | 1,247,541 | | |
$ | 0.70 | |
Series A-1 has a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
Series A-2 Preferred Stock | |
12/31/2014 | |
$ | 1,114,797 | | |
$ | 0.77 | |
Series A-2 has a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
Series A-3 Preferred Stock | |
12/31/2014 | |
$ | 795,002 | | |
$ | 0.85 | |
Series A-3 has a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
Series A-4 Preferred Stock | |
12/31/2014 | |
$ | 1,965,288 | | |
$ | 0.94 | |
Series A-4 has a 1x liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
Series B Preferred Stock | |
12/5/2015 | |
$ | 5,013,579 | | |
$ | 1.00 | |
Series B has a 1x senior liquidation preference junior to B/B1 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
The dividend rate is 6.0% Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. | |
| |
| |
| | |
| |
Series B-1 Preferred Stock | |
7/27/2017 | |
$ | 1,500,000 | | |
$ | 1.26 | |
| |
8/2/2018 | |
$ | 5,217,698 | | |
$ | 1.26 | |
| |
3/1/2019 | |
$ | 2,463,328 | | |
$ | 1.26 | |
| |
| |
| | | |
| | |
Series B-1 has a 1x senior liquidation preference junior to B2/B3 plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. | |
Preference Amounts | |
Issue Date | |
Total Face Value of Investment | | |
Issue Purchase Price/Share | |
| |
| |
| | | |
| | |
Series B-2 Preferred Stock | |
12/3/2021 | |
$ | 1,774,819 | | |
$ | 1.12 | |
| |
| |
| | | |
| | |
Series B-2 has a 1x senior liquidation preference plus participation on an as-converted to common basis, which participation is capped at 3x, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. Redemption is available by a majority vote of holders commencing after fifth anniversary from issuance, payable in three annual installments. | |
| |
| |
| | | |
| | |
Series B-3 Preferred Stock | |
12/3/2021 | |
$ | 5,327,468 | | |
$ | 1.26 | |
| |
| |
| | | |
| | |
Series B-3 has a 2x senior liquidation preference, conversion into common stock at a ratio of 1:1, limited anti-dilution protection, and voting rights on an as-converted to common basis. | |
| |
| |
| | | |
| | |
The dividend rate is 6.0%. Dividends are cumulative. Accrued and unpaid dividends are payable in shares of common stock in certain events (including an IPO) at the then current fair market value of the common stock. Redemption is available by a majority vote of holders commencing after fifth anniversary from issuance, payable in three annual installments. | |
Warrants
Warrants issued with Convertible Notes
During the years ended December 31, 2021, and
2020, the Company issued 17,286 and 58,846 warrants, respectively, to certain investors who participated over an agreed investment
minimum amount in the purchase of our convertible notes. The value of the warrants was recorded as a debt discount and expensed based
on the fair value. Just prior to the IPO, these common stock warrants were exercised on a net share basis for 60,408 common shares (451,245
pre-split shares). A loss on warrants exercised of $152,653 was recorded.
Warrants issued in connection with the IPO
In connection with the Company’s IPO, all
accrued interest on the Company's outstanding secured promissory notes were converted into (i) 426,768 post-split common shares and (ii)
426,768 post-split common stock warrants, with beneficial conversion rates charged to interest expense upon conversion. These warrants
have an exercise price of $4.35 per share.
In the IPO, the Company sold 2,165,000 units,
at a public offering price of $4.35 per unit. Each unit consisted of (i) one share of common stock and (ii) one common stock warrant (“IPO
Warrant”) with an exercise price of $4.35 per share. The common stock and the IPO Warrants were immediately separable and issued
separately in the offering. The IPO Warrants are listed and tradeable on the NASDAQ stock market, immediately exercisable at the option
of the holder, and expire five years from the date of issuance.
On April 22, 2022, the underwriters partially
exercised their over-allotment option for an additional 324,750 IPO Warrants.
In connection with the IPO, we issued to the representative
of the underwriters common stock warrants for 173,200 shares with an exercise price of $5.44 per share. The representative's warrants
are exercisable commencing October 26, 2022, and will expire on April 26, 2027.
The Company evaluated the terms of all warrants
issued at the IPO and determined that they should be classified as equity instruments based upon accounting guidance provided in ASC 480,
Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. Since the Company determined that the warrants were equity
classified, the Company recorded the proceeds from the IPO, net of issuance costs, within common stock at par value and the balance of
proceeds to additional paid in capital.
As of September 30, 2022, 2,489,750 IPO Warrants
were outstanding.
NOTE 11. NET LOSS PER SHARE OF COMMON STOCK
Basic and diluted net loss per share is computed
by dividing net loss attributable to stockholders by the weighted average number shares of common stock outstanding during the year. Potentially
dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods
presented because including them would have been antidilutive.
A reconciliation of the numerator and denominator
used in the calculation of basic and diluted net loss per share attributable to stockholders follows:
Reconciliation of loss per share | |
| | |
| | |
| | |
| |
| |
Three Months Ended September 30, | | |
Nine Months Ended September 30, | |
| |
2022 | | |
2021 | | |
2022 | | |
2021 | |
Numerator: | |
| | |
| | |
| | |
| |
Net (loss) used to compute basic and diluted loss
per common share | |
$ | (1,633,033 | ) | |
$ | (3,243,153 | ) | |
$ | (6,692,159 | ) | |
$ | (4,652,692 | ) |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Weighted average shares used to compute basic and dilutive loss per share | |
| 7,821,515 | | |
| 905,685 | | |
| 5,516,238 | | |
| 905,685 | |
The potentially dilutive shares of the
Company’s common stock resulting from the assumed exercise of outstanding stock options, warrants, and the conversion of
preferred shares are excluded from the computation of diluted net loss per share when their effect would have been anti-dilutive.
Net loss per share excluded 5,617,143 and 3,562,379 shares for the three months ended September 30, 2022, and 2021, respectively,
and 5,588,823 and 3,131,860 shares for the nine months ended September 30, 2022, and 2021, respectively.
NOTE 12. STOCK OPTION PLANS
2022 Aclarion Equity Incentive Plan
On April 21, 2022, in connection with the IPO,
the Company adopted the 2022 Aclarion Equity Incentive Plan, or “2022 Plan”. Our board of directors has appointed the compensation
committee of our board of directors as the committee under the 2022 Plan with the authority to administer the 2022 Plan. The aggregate
number of our shares of common stock that may be issued or used for reference purposes under the 2022 Plan may not exceed 2,000,000 shares,
subject to adjustments as described in the 2022 Plan.
Options granted under the 2022 Plan may be incentive
stock options or non-statutory stock options, as determined by the administrator at the time of grant of an option. Restricted stock may
also be granted under the 2022 Plan. The options vest in accordance with the grant terms and are exercisable for a period of up to 10
years from grant date.
The fair value of the options granted for the three
months and nine months ended September 30, 2022, were estimated at the date of grant using the Black-Scholes-Merton option pricing model
with the following assumptions:
Assumptions
used for valuation
Risk-free interest rate (4/2022 – 8/2022) |
|
|
1.99% |
|
Risk-free interest rate (9/2022) |
|
|
3.67% |
|
Dividend yield |
|
|
0.00 |
|
Expected term |
|
|
6-8 years |
|
Expected volatility |
|
|
66.35% |
|
Nocimed, Inc. 2015 Stock Plan
The Company maintains the Nocimed, Inc. 2015
Stock Plan, or the “Existing Plan”, under which the Company could grant 2,440,931 post-split shares or options of the
Company to our employees, consultants, and other service providers. The Company has suspended the Existing Plan in connection
with the IPO. No further awards will be granted under the Existing Plan, but awards granted prior to the suspension date will
continue in accordance with their terms and the terms of the Existing Plan.
The fair value of the options granted for the
nine months ended September 30, 2022, and 2021, were estimated at the date of grant using the Black-Scholes-Merton option pricing model
with the following assumptions:
Assumptions
used for valuation
Risk-free interest rate |
|
|
1.99% |
|
Dividend yield |
|
|
0.00 |
|
Expected term |
|
|
6-8 years |
|
Expected volatility |
|
|
25.00% |
|
Determining Fair Value of Stock Options
The fair value of each grant of stock options
was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires
significant judgment to determine.
Valuation and Amortization Method —The
Company estimates the fair value of its stock options using the Black-Scholes-Merton option-pricing model. This fair value is then amortized
over the requisite service periods of the awards.
Expected Term—The Company estimates
the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by
the simplified method.
Expected Volatility—The expected
volatility is derived from the Company’s expectations of future market volatility over the expected term of the options.
Risk-Free Interest Rate—The risk-free
interest rate is based on the U.S. Treasury yield curve on the date of grant.
Dividend Yield—The dividend yield
assumption is based on the Company’s history and expectation of no dividend payouts.
Stock Award Activity
A summary of option activity under the Company’s
incentive plans is as follows:
| |
| | | |
| | | |
| | | |
| | |
| |
Options Outstanding | | |
Weighted Average Exercise Price | | |
Weighted Average Remaining Contractual Life (In Years) | | |
Aggregate Intrinsic Value of Unexercised Options | |
Balance at December 31, 2021 | |
| 2,255,672 | | |
$ | 1.84 | | |
| 9.2 | | |
| | |
Options granted | |
| 529,619 | | |
| | | |
| | | |
| | |
Options exercised | |
| | | |
| | | |
| | | |
| | |
Options forfeited/expired | |
| (50,201 | ) | |
| | | |
| | | |
| | |
Balance at September 30, 2022 | |
| 2,735,090 | | |
$ | 1.91 | | |
| 8.6 | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at December 31, 2021 | |
| 592,532 | | |
$ | 1.58 | | |
| | | |
$ | 215,641 | |
Exercisable at September 30, 2022 | |
| 2,101,708 | | |
$ | 1.86 | | |
| | | |
$ | 0 | |
The aggregate intrinsic value in the table above
of the unexercised options reflects the total pre-tax intrinsic value (the difference between the Nasdaq closing price on September 30,
2022 and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised).
The following table summarizes the total stock-based
compensation expense included in the Company’s statements of operations for the periods presented:
Schedule of stock-based compensation expense | |
| | |
| | |
| | |
| |
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2022 | | |
2021 | | |
2022 | | |
2021 | |
| |
| | |
| | |
| | |
| |
Sales and marketing | |
$ | 848 | | |
$ | 1,850 | | |
$ | 2,544 | | |
$ | 2,890 | |
Research and development | |
| 4,272 | | |
| 10,994 | | |
| 10,401 | | |
| 12,610 | |
General and administrative | |
| 321,079 | | |
| 71,168 | | |
| 1,037,882 | | |
| 77,976 | |
Share-based compensation | |
$ | 326,199 | | |
$ | 84,012 | | |
$ | 1,050,826 | | |
$ | 93,476 | |
As of September 30, 2022, total unrecognized compensation
cost related to stock options was $615,973 and the weighted average period over which this cost is expected to be recognized is 8.6 years.
NOTE 13. SUBSEQUENT EVENTS
In accordance with Financial Accounting Standards
Board (FASB) Accounting Standards Codification (ASC) Topic 855, Subsequent Events, management has performed an evaluation of subsequent
events through the date that the financial statements were available to be issued on November 14, 2022, and has determined that it does
not have any material subsequent events to disclose in these financial statements.